Additional file 1 of Translocator protein (18kDA) (TSPO) marks mesenchymal glioblastoma cell populations characterized by elevated numbers of tumor-associated macrophages

Supplementary Fig. 1 Representative image fusion example generated with Brainlab planning software for the FOR2858 TSPO-PET imaging study. All patients received contrast-enhanced MRI, [18 F]GE180-PET and [18 F]FET-PET within a maximum of 18 and a median of 3 days before the operation. MRI included gadolinium enhanced T1- (1 mm slices) and T2‐weighted scans (2 mm slices). For [18 F]GE180-PET, approximately 180 MBq [18 F]GE180 were injected intravenously and summation scans 60–80 min post injection were used for image analysis. For [18 F]FET-PET, approximately 180 MBq [18 F]FET were injected and 40 min post injection summation images were analyzed as described previously [68]. Areas of interest were defined in an interdisciplinary exchange between the attending neurosurgeon and nuclear medicine specialist. Brainlab planning software (Brainlab, Munich, Germany) was used for image fusion and either biopsy planning, or intraoperative navigation in case of open tumor resection. [18 F] GE180 and FET uptake at the exact localization of the acquired tissue specimen were retrospectively measured by fusing the intraoperative CT or intraoperatively acquired navigation points with the PET images using a Hermes workstation (Hermes Medical Solutions, Stockholm, Sweden).